ArticlePloS one2026
Demographic and clinical characteristics of participants in the Neuropsychiatric Genetics of African Populations-Psychosis (NeuroGAP-Psychosis) study: A descriptive analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundApproximately 1.3 million individuals in sub-Saharan Africa, as well as millions of others worldwide, live with psychotic disorders. However, there is limited mental health research based on these populations and even less of a focus on neuropsychiatric genetics research within these settings.
methodsTo address this gap, the Neuropsychiatric Genetics of African Populations-Psychosis (NeuroGAP-Psychosis), a case-control study, collected data identifying genetic and environmental risk factors associated with psychotic disorders in Ethiopia, Kenya, South Africa, and Uganda. This paper describes baseline demographic and clinical characteristics of the 42,953 participants recruited between 2018-2023 and compares these characteristics by country and case status.
resultsOverall, 57.3% of participants were male (ranging from 65.8% in Ethiopia to 46.6% in Uganda). Among cases, the clinical diagnosis of schizophrenia or psychotic disorder not otherwise specified (NOS) ranged from 75.5% in Ethiopia to 44.4% in Uganda. Specific to bipolar disorder or mania NOS, the highest proportion was 53.9% in Uganda, and the lowest was 24.0% in Ethiopia. There were country-level and case-status differences across all demographic and clinical (e.g., physical comorbidities, substance use) variables.
conclusionMany factors, including language of consent, recruitment catchment areas, diagnostic practices across countries, and translation and/or cultural interpretation of the measures used in this study may account for the differences observed across countries. These findings suggest the importance of ongoing evaluation of cross-national differences to explore clinical implications and patterns of symptoms amongst geographically and culturally diverse populations. Future analyses should evaluate within-country differences to better explore these variations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.